引言2024 年 11 月份，美国临床肿瘤学会（ASCO）基于最新的循证医学证据及美国食品药品监督管理局（FDA）的药物审批动态，在其官方杂志 Journal of Clinical Oncology 上发布了两则《ASCO ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

CHICAGO -- Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC), with the ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions. With numerous ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...

Lazertinib plus amivantamab was approved based on results from the phase III MARIPOSA trial, which compared the combination with osimertinib monotherapy or lazertinib monotherapy. Lazertinib plus ...

ALXN1840 for treating Wilson disease TS ID 9950 Technology appraisal guidance TBC Alzheimer's disease (early) - gantenerumab [ID6142] Technology appraisal guidance TBC Amivantamab with carboplatin and ...